A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

Abroad (travel likely)RecruitingPHASE2

Conditions

NSCLC Stage IV · EGFR Gene Mutation

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (AND NSCLC) · hanyai@163.com

Study leads

Zhanyu Pan
Principal Investigator
Tianjin Medical University Cancer Institute and Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer Metastatic · Non-small Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Miami, United States · Basking Ridge, United States

Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient

NSCLC · Tislelizumab · Chemotherapy

Abroad (travel likely)RecruitingPHASE2

Zibo, China

Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study

NSCLC · Tislelizumab · Chemotherapy

Abroad (travel likely)RecruitingPHASE2

Zibo, China

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

NSCLC Stage IIIB · NSCLC Stage IV

Abroad (travel likely)RecruitingPHASE2

Berlin, Germany · Cologne, Germany